The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy [0.03%]
一类临床DNA聚合酶θ聚合酶结构域抑制剂ART6043的药理学特征及其增强PARP抑制剂疗效的作用机制研究
Helen M R Robinson,Vera Grinkevich,Jayesh B Majithiya et al.
Helen M R Robinson et al.
DNA polymerase theta (Polθ ) is the central component of the DNA double strand break repair process of microhomology mediated end-joining (MMEJ). Targeting Polθ for cancer therapy has been proposed due to its tumour-selective expression, ...
Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer [0.03%]
ctDNA肿瘤突变分数在晚期非小细胞肺癌免疫治疗选择中的作用
Filippo G DallOlio,Wael Zrafi,Damien Vasseur et al.
Filippo G DallOlio et al.
Background: Immune checkpoint blockers (ICBs) have transformed advanced non-small cell lung cancer (aNSCLC) treatment, but identifying patients who benefit from adding chemotherapy remains challenging, especially in PD-L1...
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial [0.03%]
阿贝西利联合福尔司特与艾伏美替尼治疗HR+/HER2-且既往接受过CDK4/6抑制剂的晚期乳腺癌患者:单臂I期临床试验
Adrienne G Waks,Elia Segui,Tianyu Li et al.
Adrienne G Waks et al.
Purpose: The efficacy of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative metastatic breast cancer is limited by resistance mechanisms, including mitogen-activated protein ki...
Divergent Tumor Immune Microenvironment and Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial [0.03%]
可切除非小细胞肺癌的新辅助化疗免疫治疗的肿瘤免疫微环境差异及反应:单组II期临床试验
Minjiang Chen,Rongzhen Li,Zuolin Cheng et al.
Minjiang Chen et al.
Background: Neoadjuvant chemoimmunotherapy improves outcomes in resectable non-small cell lung cancer (NSCLC), yet the spatial immune features associated with treatment response remain unclear. ...
Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors [0.03%]
一种转化研究平台在多种FGFR改变的实体瘤中揭示FGFR抑制剂疗效信号和耐药机制中的应用
Cinta Hierro,Mònica Sánchez-Guixé,Gabi Tarcic et al.
Cinta Hierro et al.
Purpose: The predictive value of FGFR amplifications (amp) and the role of FGFR mutations (mut) beyond known activating variants remain unclear. We aimed to establish a translational research platform to characterize FGFR...
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD [0.03%]
奥希替尼耐药T790M阴性C797S阳性的EGFR突变阳性晚期非小细胞肺癌患者中使用奥希替尼联合吉非替尼治疗的疗效:ORCHARD试验
Sarah B Goldberg,Myung-Ju Ahn,Christina Baik et al.
Sarah B Goldberg et al.
Purpose: ORCHARD (NCT03944772) was a phase II, open-label study evaluating resistance mechanisms and post-progression therapies in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung...
Circadian genotypes in PER3 and time of prostate cancer radiotherapy interact to affect risk of late side-effects [0.03%]
PER3昼夜基因型与前列腺癌放射治疗时间相互作用影响晚期副作用风险
Adam J Webb,Emily Harper,Tim Rattay et al.
Adam J Webb et al.
Purpose: We showed previously that breast cancer patients with certain circadian rhythm genotypes have higher incidences of toxicity when treated with radiotherapy at different times of day. This opens the way to genetica...
Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes [0.03%]
靶向核素治疗:当前格局及联合治疗策略以改善肿瘤预后
Julie Nonnekens,Lauren A Byers,Aman Chauhan et al.
Julie Nonnekens et al.
Targeted radionuclide therapy (TRT) is an emerging modality in oncology that delivers internal radiation specifically to tumor sites. It typically consists of a particle-emitting radionuclide, a linking complex with a chelator for securely ...
The novel hypomethylating agent NTX-301 reprograms epigenetic and Hippo signaling pathways and exhibits pre-clinical activity in venetoclax-resistant and TP53-mutant AML [0.03%]
新型低甲基化药物NTX-301重编程表观遗传和Hippo信号通路,并在维奈克拉耐药和TP53突变的急性髓系白血病小鼠模型中表现出临床前活性
Bing Z Carter,Po Yee Mak,Suresh Satpati et al.
Bing Z Carter et al.
Background: Hypomethylating agent (HMA) and the BCL-2 inhibitor venetoclax (VEN) combinations have evolved into frontline therapies for patients with acute myeloid leukemia (AML), yielding high response rates. However, mo...
Komal Gupta,Daniel S W Tan,Regina Hoo
Komal Gupta
A recent article presents the largest histo-genomic characterisation of first-line osimertinib resistance from ORCHARD study. Dual-modality tissue and plasma sequencing detected resistance alterations in 87% and polyclonal mechanisms in 46%...